Erik Boot

List of Publications by Year in Descending Order

53 papers	1,890 citations	23 h-index	43 g-index
62 ext. papers	2,386 ext. citations	5.8 avg, IF	4.28 L-index

#	Paper	IF	Citations
53	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. *Molecular Psychiatry*, **2021**, 26, 4496-4510	15.1	39
52	Cognitive behavioral therapy in 22q11.2 deletion syndrome: A case study of two young adults with an anxiety disorder. *Journal of Intellectual Disabilities*, **2021**, 25, 695-704	1.8	1
51	Possible underreporting of pathogenic variants in RAI1 causing Smith-Magenis syndrome. *American Journal of Medical Genetics, Part A*, **2021**, 185, 3167-3169	2.5	4
50	Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders: The Power of 1. *Neurology*, **2021**, 96, 529-540	6.5	15
49	22q11.2 microdeletion and increased risk for type 2 diabetes. *EClinicalMedicine*, **2020**, 26, 100528	11.3	2
48	Age-Related Parkinsonian Signs in Microdeletion 22q11.2. *Movement Disorders*, **2020**, 35, 1239-1245	7	2
47	Personalized medical information card for adults with 22q11.2 deletion syndrome: An initiative to improve communication between patients and healthcare providers. *Journal of Applied Research in Intellectual Disabilities*, **2020**, 33, 1534-1540	2.2	0
46	A genetic model for multimorbidity in young adults. *Genetics in Medicine*, **2020**, 22, 132-141	8.1	9
45	Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review. *American Journal of Medical Genetics, Part A*, **2019**, 179, 2292-2306	2.5	5
44	All-cause mortality and survival in adults with 22q11.2 deletion syndrome. *Genetics in Medicine*, **2019**, 21, 2328-2335	8.1	19
43	Rare copy number variations affecting the synaptic gene DMXL2 in neurodevelopmental disorders. *Journal of Neurodevelopmental Disorders*, **2019**, 11, 3	4.6	4
42	Neurobiological perspective of 22q11.2 deletion syndrome. *Lancet Psychiatry,the*, **2019**, 6, 951-960	23.3	28
41	Low prevalence of substance use in people with 22q11.2 deletion syndrome. *British Journal of Psychiatry*, **2019**, 215, 661-667	5.4	8
40	22q11.2 Deletion Syndrome-Associated Parkinson's Disease. *Movement Disorders Clinical Practice*, **2019**, 6, 11-16	2.2	12
39	Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome. *American Journal of Medical Genetics, Part A*, **2018**, 176, 936-944	2.5	26
38	Non-pharmacological treatment of psychiatric disorders in individuals with 22q11.2 deletion syndrome; a systematic review. *American Journal of Medical Genetics, Part A*, **2018**, 176, 1742-1747	2.5	8
37	Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. *Psychiatry Research - Neuroimaging*, **2018**, 272, 65-70	2.9	5

36	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. *Neurology*, **2018**, 90, e2059-e2067	6.5	25
35	A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinson's disease and schizophrenia. *Science Advances*, **2018**, 4, eaar6637	14.3	21
34	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. *American Journal of Medical Genetics, Part A*, **2018**, 176, 2146-2159	2.5	13
33	Internet Safety Issues for Adolescents and Adults with Intellectual Disabilities. *Journal of Applied Research in Intellectual Disabilities*, **2017**, 30, 416-418	2.2	28
32	Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia. *Current Opinion in Psychiatry*, **2017**, 30, 191-196	4.9	61
31	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. *Brain*, **2017**, 140, 1371-1383	11.2	30
30	Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome. *American Journal of Psychiatry*, **2017**, 174, 1054-1063	11.9	58
29	Obesity in adults with 22q11.2 deletion syndrome. *Genetics in Medicine*, **2017**, 19, 204-208	8.1	37
28	Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. *PLoS ONE*, **2016**, 11, e0159928	3.7	16
27	Cardiac sympathetic activity in 22q11.2 deletion syndrome. *International Journal of Cardiology*, **2016**, 212, 346-51	3.2	1
26	Practical guidelines for managing adults with 22q11.2 deletion syndrome. *Genetics in Medicine*, **2015**, 17, 599-609	8.1	154
25	Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. *JAMA Psychiatry*, **2015**, 72, 377-85	14.5	139
24	PRODH rs450046 and proline x COMT Val□□Met interaction effects on intelligence and startle in adults with 22q11 deletion syndrome. *Psychopharmacology*, **2015**, 232, 3111-22	4.7	9
23	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. *American Journal of Medical Genetics, Part A*, **2015**, 167A, 639-45	2.5	43
22	Parkinsonism in phenylketonuria: a consequence of dopamine depletion?. *JIMD Reports*, **2015**, 20, 35-8	1.9	13
21	Functional analysis of novel genetic variation in the thyroid hormone activating type 2 deiodinase. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E2429-36	5.6	7
20	Serotonergic, noradrenergic and dopaminergic markers are related to cognitive function in adults with 22q11 deletion syndrome. *International Journal of Neuropsychopharmacology*, **2014**, 17, 1159-65	5.8	11
19	Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. *American Journal of Psychiatry*, **2014**, 171, 627-39	11.9	472

18	Enhanced maternal origin of the 22q11.2 deletion in velocardiofacial and DiGeorge syndromes. *American Journal of Human Genetics*, **2013**, 92, 439-47	11	39
17	Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes. *American Journal of Human Genetics*, **2013**, 92, 637	11	78
16	Poster #106 STARTLE REACTIVITY AND PREPULSE INHIBITION OF THE ACOUSTIC STARTLE RESPONSE ARE MODULATED BY COMT VAL MET POLYMORPHISM IN ADULTS WITH 22Q11 DELETION SYNDROME. *Schizophrenia Research*, **2012**, 136, S223-S224	3.6	
15	Startle reactivity and prepulse inhibition of the acoustic startle response are modulated by catechol-O-methyl-transferase Val(158) Met polymorphism in adults with 22q11 deletion syndrome. *Journal of Psychopharmacology*, **2012**, 26, 1548-60	4.6	12
14	Overexpression of chromosome 15q11-q13 gene products: a risk factor for schizophrenia and associated psychoses?. *American Journal of Psychiatry*, **2012**, 169, 96-7; author reply 97	11.9	5
13	Functional gene-expression analysis shows involvement of schizophrenia-relevant pathways in patients with 22q11 deletion syndrome. *PLoS ONE*, **2012**, 7, e33473	3.7	24
12	White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. *Schizophrenia Research*, **2011**, 132, 75-83	3.6	36
11	Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. *PLoS ONE*, **2011**, 6, e21685	3.7	26
10	Unexpected detection of nodular melanoma of the skin on the scalp by I-123 IBZM brain SPECT. *Clinical Nuclear Medicine*, **2011**, 36, 148-9	1.7	0
9	Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. *EJNMMI Research*, **2011**, 1, 37	3.6	130
8	COMT Val(158) met genotype and striatal D(2/3) receptor binding in adults with 22q11 deletion syndrome. *Synapse*, **2011**, 65, 967-70	2.4	15
7	Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val□/□Met polymorphism, gender and symptomatology. *Journal of Psychopharmacology*, **2011**, 25, 888-95	4.6	21
6	Striatal D□receptor binding in 22q11 deletion syndrome: an [□□I]IBZM SPECT study. *Journal of Psychopharmacology*, **2010**, 24, 1525-31	4.6	20
5	Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome: Potential role for dopamine transporter imaging. *American Journal of Medical Genetics, Part A*, **2010**, 152A, 2937-8	2.5	39
4	Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. *Neuropsychopharmacology* , **2008**, 33, 1252-8	8.7	46
3	AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. *European Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 35, 1350-6	8.8	34
2	Pericardial and bilateral pleural effusion associated with clozapine treatment. *European Psychiatry*, **2004**, 19, 65	6	7
1	Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. *Psychopharmacology*, **2000**, 150, 347-8	4.7	25